Pharvaris (PHVS) Net Income towards Common Stockholders (2020 - 2026)
Pharvaris (PHVS) posted Net Income towards Common Stockholders of -$45.8 million for Q1 2026, up 15.14% on a QoQ basis from -$53.9 million in Q4 2025, and up 6.35% year-over-year from -$43.0 million in Q1 2025.
Pharvaris (PHVS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Pharvaris' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$45.8 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 6.35% year-over-year to -$45.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$91.4 million (up 8.54% YoY) and the FY2025 annual result came in at -$198.5 million, down 36.64% from the prior year.
- Net Income towards Common Stockholders was -$45.8 million for Q1 2026 at Pharvaris, up from -$53.9 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $51.8 million in Q2 2025 and bottomed at -$53.9 million in Q4 2025.
- A 5-year average of -$19.8 million and a median of -$30.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders surged 174.08% — and 2023, when it slumped 207.77%.
- Pharvaris' Net Income towards Common Stockholders stood at -$40.1 million in 2022, then advanced by 12.26% to -$35.2 million in 2023, then slipped by 5.39% to -$37.1 million in 2024, then plunged by 45.4% to -$53.9 million in 2025, then increased by 15.14% to -$45.8 million in 2026.
- Business Quant data shows PHVS's Net Income towards Common Stockholders at -$45.8 million in Q1 2026, -$53.9 million in Q4 2025, and -$43.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Pharvaris | 2.22 Bn | 1.94 Bn | - | -45.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.78 Mn |
| Dec 31, 2025 | -53.94 Mn |
| Sep 30, 2025 | -43.43 Mn |
| Jun 30, 2025 | 51.78 Mn |
| Mar 31, 2025 | -48.88 Mn |
| Dec 31, 2024 | -37.10 Mn |
| Sep 30, 2024 | -45.92 Mn |
| Jun 30, 2024 | 31.99 Mn |
| Mar 31, 2024 | -30.40 Mn |
| Dec 31, 2023 | -35.20 Mn |
| Sep 30, 2023 | -25.69 Mn |
| Jun 30, 2023 | 23.84 Mn |
| Mar 31, 2023 | -24.32 Mn |
| Dec 31, 2022 | -40.12 Mn |
| Sep 30, 2022 | -8.35 Mn |
| Jun 30, 2022 | 13.56 Mn |
| Mar 31, 2022 | -17.98 Mn |
| Dec 31, 2021 | 34,764.73 Bn |
| Sep 30, 2021 | -10.78 Mn |
| Jun 30, 2021 | -18.31 Mn |